Invasive Breast Cancer, Breast Cancer Mortality Increased Long Term After DCIS
2024-01-25
临床结果
THURSDAY, Jan. 25, 2024 -- Women with non-screen-detected ductal carcinoma in situ have an increased risk for invasive breast cancer and breast cancer death, according to a study published online Jan. 24 in The BMJ.
Gurdeep S. Mannu, M.B.B.S., D.Phil., from the University of Oxford in the United Kingdom, and colleagues examined the long-term risks for invasive cancer and death related to breast cancer after non-screen-detected ductal carcinoma in situ among 27,543 women in England who were diagnosed during 1990 to 2018, outside the National Health Service breast screening program.
The researchers found that by Dec. 31, 2018, 3,651 women with non-screen-detected ductal carcinoma in situ had developed invasive breast cancer (ratio of observed to expected rate, 4.21). Throughout follow-up, the ratio of observed to expected rate of developing invasive breast cancer remained elevated among women aged younger than 45 to 70 years. The 25-year cumulative risks for invasive breast cancer were 27.3, 25.2, 21.7, and 20.8 percent for those with a diagnosis of ductal carcinoma in situ at age younger than 45, 45 to 49, 50 to 59, and 60 to 70 years, respectively. Overall, 908 women died of breast cancer (ratio of observed to expected rate, 3.83); the ratio remained elevated throughout follow-up. The 25-year cumulative risks for breast cancer death were 7.6, 5.8, 5.9, and 6.2 percent, respectively, by age at diagnosis.
"These findings should inform considerations regarding the frequency and duration of surveillance following a diagnosis of ductal carcinoma in situ, particularly for women diagnosed at younger ages," the authors write.
Abstract/Full Text
Editorial
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-药物
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。